Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry

Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry

(2014) Jacek Musijowski et al.   JOURNAL OF SEPARATION SCIENCE

Forensic analysis of mesembrine alkaloids in Sceletium tortuosum by nonaqueous capillary electrophoresis mass spectrometry

(2012) Jörg Roscher et al.   ELECTROPHORESIS

Implementation of a design of experiments to study the influence of the background electrolyte on separation and detection in non-aqueous capillary electrophoresis-mass spectrometry

(2012) Tjorben Nils Posch et al.   ELECTROPHORESIS

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

(2011) Stéphane Bouchet et al.   CLINICA CHIMICA ACTA

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma

(2011) Lutz Götze et al.   CLINICA CHIMICA ACTA

Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: Application to an explorative study

(2011) Michael Rodamer et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry

(2010) R. Honeywell et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Sunitinib

(2009) Georgios S. Papaetis et al.   BIODRUGS

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma

(2009) Benoit Blanchet et al.   CLINICA CHIMICA ACTA

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma

(2009) Marie-Christine Etienne-Grimaldi et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

(2009) A. Haouala et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography–electrospray ionization-tandem mass spectrometry and pharmacokinetic application

(2009) Qingyu Zhou et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

(2009) Peter de Bruijn et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆

(2008) P MINKIN et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES